Remove Electronics Remove Networking Remove Safety Remove Side effects
article thumbnail

Cerner Enviza and FDA partner to develop AI drug safety tools

Pharmaceutical Technology

Oracle company Cerner Enviza and John Snow Labs have collaborated with the US Food and Drug Administration (FDA) for the development of artificial intelligence (AI) tools for drug safety and real-world evidence studies. During the two-year project, the companies will assess the mental health side effects of the asthma drug, montelukast.

Safety 59
article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

Over the past few years, we have researched the types of evidence used in regulatory decisions for drug product withdrawals due to safety concerns in Europe. But from a safety point of view, observational studies can be more representative of the population the drug will serve.

Safety 109
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How can evidence-based medicine (EBM) methodology support drug withdrawals?

European Pharmaceutical Review

Withdrawing drugs over safety concerns requires careful analysis of the health benefits and risks by regulators. Monitoring and studying the side effects of licensed medicines is an essential part of drug development to ensure public safety. Supporting regulators. It focused on data from France, Germany and the UK.

article thumbnail

How Real-World Data Can Contribute to Improved Mental Health Treatment

PM360

Carl Marci, Chief Psychiatrist and Managing Director of Mental Health and Neuroscience at OM1 , about how the company is using its Mental Health and Neuroscience Real-World Data Network to help improve personalized treatment for mental health patients and increase awareness about issues related to mental health disorders.

article thumbnail

How using AI in clinical trials accelerates drug development

Pharmaceutical Technology

But before pharmaceutical companies can go to market with a breakthrough drug, they need to ensure safety and efficacy through clinical trials. Pharma companies need tools like AI that can reliably improve this percentage without jeopardizing safety. The need for new medical treatments and drugs has never been greater.

article thumbnail

10 New Solutions, Strategies, and Devices to Boost Adherence

PM360

DrFirst’s core business of electronic medication management puts the company in a unique position to improve medication adherence with Timely. Care providers can view adherence data, patient-reported side effects, and connect directly to their patients if needed. Jennifer DiGennaro. jdigennaro@drfirst.com.